Factors Affecting the Survival of Therapy Related AML/MDS, Secondary AML and De Novo AML

被引：0
|
作者：
Mushtaq, Rao [1 ]
Akbar, Faisal [2 ]
Khan, Israa [3 ]
Isom, Scott [4 ]
Pardee, Timothy [4 ]
Howard, Dianna S. [4 ]
Powell, Bayard L. [4 ]
机构：
[1] Univ Colorado, Aurora, CO USA
[2] Wake Forest Univ, Dept Med, Lewisville, NC USA
[3] Univ Colorado, Sch Med, Childrens Hosp Colorado, Dept Pediat Hosp Med, Aurora, CO USA
[4] Wake Forest Baptist Hlth, Comprehens Canc Ctr, Winston Salem, NC USA
来源：
BLOOD | 2018年 / 132卷
关键词：
D O I：
10.1182/blood-2018-99-110191
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5199
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Prognostic factors predicting survival in de novo AML patients requiring intensive care
    Schellongowski, Peter
    Staudinger, Thomas
    Laczika, Klaus
    Locker, Gottfried
    Bojic, Andja
    Jaeger, Ulrich
    Valent, Peter
    Sperr, Wolfgang R.
    BLOOD, 2007, 110 (11) : 841A - 841A
  • [32] Concerning survival signal for eltrombopag in MDS/AML
    Tao, Derrick
    Prasad, Vinay
    LEUKEMIA & LYMPHOMA, 2020, 61 (04) : 1002 - 1003
  • [33] Day 14 Bone Marrow Cellularity Is Superior to CD34 Immunohistochemistry in Predicting Complete Remission in De Novo AML but Not in Secondary/Therapy-Related AML
    Zheng, G.
    Dezern, A.
    Pratz, K. W.
    Karp, J. E.
    Gocke, C.
    MODERN PATHOLOGY, 2013, 26 : 371A - 371A
  • [34] Day 14 Bone Marrow Cellularity Is Superior to CD34 Immunohistochemistry in Predicting Complete Remission in De Novo AML but Not in Secondary/Therapy-Related AML
    Zheng, G.
    Dezern, A.
    Pratz, K. W.
    Karp, J. E.
    Gocke, C.
    LABORATORY INVESTIGATION, 2013, 93 : 371A - 371A
  • [35] AML and MDS Following Radiation Therapy Are Similar to De Novo Disease and Differ from Other Therapy-Related Myeloid Neoplasms
    Nardi, V.
    Kluk, M.
    Attar, E.
    Winkfield, K.
    Hasserjian, R. P.
    LABORATORY INVESTIGATION, 2011, 91 : 309A - +
  • [36] Magrolimab in MDS and AML
    Cookson, Emma
    LANCET HAEMATOLOGY, 2020, 7 (07): : E505 - E505
  • [37] MDS PROGRESSION TO AML
    Murray, Cindy
    LEUKEMIA RESEARCH, 2021, 108 : S60 - S60
  • [38] Outcomes for Allogeneic Stem Cell Transplantation in Secondary AML Are Inferior to De Novo AML and Are Independent of the Disease Risk Index
    Perram, Jacinta
    Mayson, Eleni
    Tang, Catherine
    Tran, Steven
    Aarons, Donna
    Dodds, Anthony J.
    Fay, Keith
    Hamad, Nada
    Ma, David
    Milliken, Sam
    Withers, Barbara
    Greenwood, Matthew
    Stevenson, William S.
    Arthur, Christopher Kevin
    Kerridge, Ian H.
    Moore, John
    BLOOD, 2021, 138
  • [39] Differences in cell lineage involvement between MDS-AML and de novo AML studied by fluorescence in situ hybridization in combination with morphology
    Bernell, P
    Arvidsson, I
    Hast, R
    Jacobsson, B
    Stenke, L
    EUROPEAN JOURNAL OF HAEMATOLOGY, 1997, 58 (04) : 241 - 245
  • [40] Clinical and Molecular Insights into the Classification Dilemma: Are MDS/AML Cases Distinct from Secondary AML?
    Kewan, Tariq
    Durmaz, Arda
    Bahaj, Waled
    Gurnari, Carmelo
    Ogbue, Olisaemeka
    Kiwan, Ahmad
    Awada, Hussein
    Carraway, Hetty E.
    Balasubramanian, Suresh Kumar
    Bat, Taha
    Madanat, Yazan F.
    Visconte, Valeria
    Maciejewski, Jaroslaw
    BLOOD, 2024, 144 : 850 - 851
12345